RESEARCH PEPTIDE FUNDAMENTALS
Frequently asked questions
Plain-language answers to common questions about the four research peptides covered on this desk, with citations to the underlying literature.
What is tesamorelin?
Tesamorelin is a synthetic 44-amino-acid analogue of human growth hormone-releasing hormone (GHRH), FDA-approved in 2010 to reduce excess abdominal fat in HIV-infected adults with antiretroviral-related lipodystrophy [2]. It stimulates the pituitary to secrete more growth hormone, which drives visceral fat loss. The approval is narrow; every other use is investigational [7].
What does tesamorelin do?
In its approved clinical setting, tesamorelin reduces visceral adipose tissue (the fat around internal organs), lowers serum triglycerides, increases IGF-1, and modestly increases lean body mass [1]. These effects are sustained during continued use but reverse after discontinuation [5]. Outside the HIV lipodystrophy population, the evidence base for comparable effects is much thinner.
How does tesamorelin work?
It binds the GHRH receptor on anterior-pituitary somatotroph cells, triggering cAMP/PKA signaling that drives GH synthesis and pulsatile secretion. The GH produced then signals the liver to generate IGF-1, and together GH and IGF-1 promote lipolysis in visceral adipose tissue. A structural modification (N-terminal trans-3-hexenoic acid) blocks the enzyme that would otherwise quickly degrade native GHRH in circulation [4].
Will tesamorelin help me lose belly fat?
The clinical trials demonstrating visceral-fat reduction were conducted exclusively in HIV-positive adults on antiretroviral therapy [1][3][6]. The mechanism is not inherently HIV-specific — GHRH receptor agonism is a systemic pathway — but no large RCT has been conducted in a general non-HIV population. 'Mechanistically plausible' is not the same as 'demonstrated by controlled evidence.' We cannot answer this question for individuals, and we do not give medical advice.
What is semaglutide?
Semaglutide is a synthetic, long-acting analogue of GLP-1 (glucagon-like peptide-1), an endogenous intestinal hormone. It is FDA-approved for type 2 diabetes, chronic weight management, cardiovascular risk reduction in people with established cardiovascular disease and obesity, and (since 2025) metabolic steatohepatitis (MASH). It works by activating GLP-1 receptors in the pancreas, gut, and brain.
What is semaglutide used for?
Its approved uses span metabolic disease: lowering blood sugar in type 2 diabetes, reducing body weight in people with obesity, cutting cardiovascular event risk in people with existing cardiovascular disease and overweight/obesity [10], and slowing major kidney-disease events in type 2 diabetes with chronic kidney disease [9]. Each of these indications is supported by large, phase-3 controlled trials with pre-specified hard endpoints.
How does semaglutide work?
It binds GLP-1 receptors on pancreatic beta cells (stimulating insulin secretion in proportion to blood glucose), alpha cells (suppressing glucagon), and on gastric smooth muscle (slowing emptying). Its appetite-reducing effect is primarily central: semaglutide reaches hypothalamic appetite circuits where it activates anorexigenic neurons and suppresses hunger-promoting ones, reducing food intake and modifying food preference [11].
How does semaglutide work for weight loss?
Weight loss from semaglutide is primarily driven by central appetite suppression — not increased metabolic rate or fat-specific burning. People consistently describe a reduction in 'food noise' (the background preoccupation with eating) and earlier satiety. In STEP 1, this produced a mean weight reduction of 14.9% at 68 weeks versus 2.4% with placebo [11]. Weight largely returns after the drug is stopped, which is why obesity pharmacotherapy is characterized as chronic rather than curative.
What is thymosin alpha-1?
Thymosin alpha-1 (thymalfasin) is a 28-amino-acid peptide derived from thymus tissue that modulates the innate-adaptive immune interface. It is approved as a drug in more than 35 countries but not in the US. It should not be confused with thymosin beta-4 (TB-500), which is a completely different peptide with a different sequence, different mechanism, and WADA-prohibited status [14].
What does thymosin alpha-1 do?
It signals through TLR2 and TLR9 on dendritic cells and monocytes, promoting T-cell maturation and Th1 immune polarization. It has been studied as a treatment for chronic viral hepatitis, sepsis, cancer combination therapy, and COVID-19 [14][16]. The largest high-quality sepsis trial (TESTS, 2025, n=1,106) found no mortality benefit [13], which should be the starting point for any expectation-setting.
What is thymosin alpha-1 used for?
Where it is approved (outside the US), thymalfasin has been used primarily for chronic hepatitis B and C, and in some countries as an immunostimulant in cancer care. In research contexts it has also been studied for sepsis, COVID-19 immune reconstitution, and general immune support [14][15][16]. Its US availability is limited to investigational or compounding settings.
Is thymosin alpha-1 FDA-approved?
No. Thymosin alpha-1 (thymalfasin) is not FDA-approved for marketing in the United States. It is approved in more than 35 other countries [14], but US access is investigational or via compounding only. The 2025 phase-3 TESTS trial returned a null result in sepsis [13], which has not strengthened the case for US approval.
What is PT-141?
PT-141 is the research-chemical name for bremelanotide, a synthetic cyclic heptapeptide that activates melanocortin receptors (MC4R and MC3R) in the brain. FDA-approved in 2019 as bremelanotide injection for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women [22]. The 'PT-141' designation is how it circulates in the research-use community; the approved pharmaceutical form is bremelanotide.
What is PT-141 peptide?
PT-141 (bremelanotide) is a cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (alpha-MSH). It is distinct from melanotan II (a non-selective full MC1–5 agonist) and should not be conflated with it. Its selectivity for MC3R/MC4R is the basis of its central, desire-focused mechanism rather than the skin-darkening and non-selective effects of melanotan II [19].
What does the PT-141 peptide do?
In the approved indication, bremelanotide increases sexual desire and reduces desire-related distress in premenopausal women with HSDD, as demonstrated in two phase-3 RCTs [20]. The mechanism is central — it activates hypothalamic melanocortin circuits involved in sexual motivation rather than acting on vascular smooth muscle. The most common side effect is nausea, reported by roughly 40% of long-term users [21].
What is PT-141 used for?
The FDA-approved use is hypoactive sexual desire disorder (HSDD) in premenopausal women only [22]. Off-label research-community use includes men (for erectile function and desire) and postmenopausal women, but these uses are not approved and have not been established by pre-registered large RCTs meeting hard primary endpoints. A transient blood-pressure increase is a documented caution; use in people with uncontrolled hypertension or cardiovascular disease is contraindicated per the prescribing label [22].